共 158 条
[1]
Thomsen SF(2014)Atopic dermatitis: natural history, diagnosis, and treatment ISRN Allergy. 2014 1254-1261
[2]
Chen TL(2022)Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with janus kinase inhibitors: a systematic review and meta-analysis JAMA Dermatol 158 84-92
[3]
Lee LL(2019)Pathophysiology of atopic dermatitis: clinical implications Allergy Asthma Proc 40 783-798
[4]
Huang HK(2020)Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib Am J Clin Dermatol 21 814-826
[5]
Chen LY(2021)The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases J Allergy Clin Immunol 147 2020-8-5-940
[6]
Loh CH(2020)Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib Drugs Context. 9 927-873
[7]
Chi CC(2021)JAK inhibitors in the treatment of atopic dermatitis J Allergy Clin Immunol 148 609-443
[8]
Kim J(2022)Correction to: Abrocitinib: first approval Drugs 82 863-532
[9]
Kim BE(2020)Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial JAMA Dermatol 156 434-14
[10]
Leung DYM(2022)Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis J Eur Acad Dermatol Venereol 36 523-754